The Latest SPAC News and Rumors: June 14, 2022
by Marlena Haddad on 2022-06-14 at 11:39am

 


Below is a daily summary of links to the latest SPAC news and rumors gathered across the web. 

Latest SPAC News: Financial firms push back on SEC, Polestar to debut electric roadster concept, and DNEG announces business update 


U.S. financial firms push back on SEC bid to rein-in blank check company deals

U.S. financial industry groups are pushing to water down a draft Securities and Exchange Commission (SEC) rule aimed at reining-in special purpose acquisition companies or SPACs, arguing it could kill the industry.

The American Securities Association (ASA), the SPAC Association and the CFA Institute are among groups warning that the SEC’s proposed March rule would create too much liability for parties involved in SPAC deals, and as such goes further than traditional initial public offering (IPO) and M&A rules.

READ


Polestar to Debut Polestar 5 Electric Performance 4-Door GT Prototype and Polestar 2 BST Edition 270 at 2022 Goodwood Festival of Speed

Polestar, the Swedish electric performance car company, is returning to the Goodwood Festival of Speed on 23 June 2022 and will debut a Polestar 5 prototype and the new high-performance, limited-edition Polestar 2 BST edition 270. Polestar’s electric roadster concept and its existing product range will also be present.

Polestar intends to list on the Nasdaq in a proposed business combination with Gores Guggenheim, Inc. (Nasdaq: GGPI, GGPIW, and GGPIU), which is expected to close in June 2022.

READ

Visual Effects and Animation Leader DNEG Announces Business Update

DNEG, a leading technology-enabled visual effects (VFX) and animation company for the creation of feature film, television and multiplatform content, today announced a business update for the year ended March 31, 2022.

For the full-year ended March 31, 2022, DNEG generated revenue of $409.3 million, Net Income of $39.3 million and Adjusted EBITDA of $100.6 million, equating to year-over-year growth of 33.5%, 214.7% and 22.4%, respectively. Additionally, Net Income margin equated to 9.6% and Adjusted EBITDA margin equated to 24.6% for the year.

As previously announced, DNEG entered into a Business Combination Agreement with Sports Ventures Acquisition Corp (“Sports Ventures”), a publicly-traded special purpose acquisition company (Nasdaq: AKIC), in January, 2022.

READ

Recent Posts
by Nicholas Alan Clayton on 2024-04-18 at 11:50am

AGBA (NASDAQ:AGBA) stock is up over +90% this morning following a +211% premarket spike on news it has signed a definitive agreement to combine with social streaming video platform Triller. AGBA, the company itself, was formed by the $555 million combination between a SPAC of the same name and TAG Companies, a financial services firm...

by Nicholas Alan Clayton on 2024-04-18 at 7:57am

At the SPAC of Dawn Since closing its combination with DHC last month, AI customer engagement firm BEN (NASDAQ:BNAI) has rolled out new partnerships with call center and healthcare clients. And, while it faces a fair bit of competition in the chatbot realm, several high-profile institutions have demonstrated that creating one that provides useful services...

by Nicholas Alan Clayton on 2024-04-17 at 3:05pm

Blue Ocean (NASDAQ:BOCN) provided significantly more texture today in the presentation for its $275 million combination with Asian digital media group TNL Mediagene, which it expects to hit profitability in the second half of the year despite a slight shakeup in financing for the transaction. The first big update in the first investor deck is...

by Nicholas Alan Clayton on 2024-04-17 at 8:13am

At the SPAC of Dawn A brand new market may have just opened up for space de-SPACs as NASA administrator Bill Nelson announced a shift in the agency’s $11 billion program for a mission to return samples from Mars. Rather than rely on the agency’s internal technologies that would be predicted to get a sample...

by Nicholas Alan Clayton on 2024-04-16 at 11:33am

Overall deal flow between SPACs and biotech firms has slowed over the last year, but some pending FDA changes could breathe new life into particular business models within the space. In particular, the FDA has asked Congress as part of its 2025 Legislative Proposals to eliminate the interchangeability designation for biosimilar medications, claiming the existing...

logo

Copyright © 2023 SPACInsider, Inc. All Rights Reserved